| Current Price | $2.22 | Mkt Cap | $247.2M |
|---|---|---|---|
| Open | $2.16 | P/E Ratio | -0.85 |
| Prev. Close | $2.22 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.06 - $2.30 | Volume | 2,708,233 |
| 52-Wk Range | $1.43 - $10.99 | Avg. Daily Vol. | 4,391,570 |
| Current Price | $2.22 | Mkt Cap | $247.2M |
|---|---|---|---|
| Open | $2.16 | P/E Ratio | -0.85 |
| Prev. Close | $2.22 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.06 - $2.30 | Volume | 2,708,233 |
| 52-Wk Range | $1.43 - $10.99 | Avg. Daily Vol. | 4,391,570 |
The best Bull and Bear pitches based on recency and number of recommendations.
Pure-play biosimilar company. Getting killed on today's CRL. Company said no capital raise and issues can be fixed in a few months. Long-term thesis isn't busted (yet) so worth a green thumb in CAPS.
Read the most recent pitches from players about CHRS.
Recs
LazyHarlequin
(91.25)
Submitted: 7/8/2019 1:04:22 PM :
Start Price:
$17.87
NASDAQ:CHRS Score:
+142.54
On 7/8/19 down $4+ to $19. Options available, but no LEAPs.
Recs
Bigsef77
(49.64)
Submitted: 2/18/2019 9:42:19 AM :
Start Price:
$13.96
NASDAQ:CHRS Score:
-150.18
Here's Why Coherus BioSciences Rose 48.7% in January
[Motley Fool]
Maxx Chatsko, The Motley Fool
,Motley Fool•February 11, 2019
What happened
Shares of Coherus BioSciences (NASDAQ: CHRS) gained nearly 49% last month, according to data provided by S&P Global Market Intelligence. The company announced a global settlement with AbbVie that will allow the small-cap biopharma to commercialize a biosimilar to Humira, which was developed as CHS-1420. The pair had previously sparred over patents related to formulating the antibody.
The settlement gives Coherus Biosciences a license to the formulation patents, although it won't be able to sell CHS-1420 in the United States until December 2023. Additionally, it will have to provide royalties to AbbVie on all domestic sales just for using the patent portfolio. Given the size of the market, investors seem to think that won't matter in the end. Are they right?
Recs
dlm777
(< 20)
Submitted: 7/14/2017 10:00:40 AM :
Start Price:
$13.85
NASDAQ:CHRS Score:
+171.87
nothing in the pipeline ?
Find the members with the highest scoring picks in CHRS.
murphydevani (< 20) Score: +220.26
The Score Leader is the player with the highest score across all their picks in CHRS.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| murphydevani | < 20 | 8/21/2015 |
|
5Y | $28.55 | -92.14% | +128.13% | +220.26 | 1 Comment | |
| dlm777 | < 20 | 7/14/2017 |
|
3M | $13.85 | -83.79% | +88.08% | +171.87 | 1 Comment | |
| LazyHarlequin | 91.25 | 7/8/2019 |
|
5Y | $17.87 | -87.44% | +55.11% | +142.54 | 1 Comment | |
| ababrmon | < 20 | 6/21/2023 |
|
5Y | $3.76 | -40.29% | +5.68% | -45.97 | 0 Comment | |
| ak1010 | 99.67 | 7/24/2023 |
|
5Y | $4.19 | -46.42% | +1.37% | -47.79 | 0 Comment | |
| Tangoko | < 20 | 9/18/2023 |
|
3M | $4.42 | -49.15% | +3.94% | -53.09 | 0 Comment | |
| GW1000 | 84.97 | 7/23/2021 |
|
5Y | $13.00 | -82.73% | +4.68% | -87.41 | 0 Comment | |
| nangofandango | 37.73 | 3/15/2022 |
|
5Y | $12.23 | -81.64% | +9.63% | -91.27 | 0 Comment | |
| Hongkong | < 20 | 6/2/2021 |
|
3Y | $13.17 | -82.95% | +9.47% | -92.43 | 0 Comment | |
| Jumpersfor | < 20 | 6/11/2021 |
|
5Y | $14.24 | -84.23% | +8.48% | -92.71 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
